- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Los Alamos National Laboratory (LANL) has selected Manhattan Isotopes Technology, LLC and Vista Therapeutics, Inc. as recipients of $100,000 awards from the Los Alamos National Security, LLC Venture Acceleration Fund.
The Venture Acceleration Fund (VAF) invests in innovative Northern New Mexico companies seeking to commercialize technology and take it to market faster. VAF investments help the companies and their technologies reach the next level of success through business development activities such as proof-of-concept, prototyping, securing initial customers, or additional funding. Projects with an association with LANL technology or expertise receive preference for funding.
The VAF program fills a unique need by providing capital that reduces a company's risk. "Without this type of funding, projects can languish or take much longer to come to fruition," says said David Pesiri, the Laboratory's Technology Transfer Division leader. "Our team also works closely with the companies during their contract period to connect them with other resources—like mentors, customers, and contacts—that will make them more successful in the long run.
Manhattan Isotope Technology, LLC is a Los Alamos start-up company that will supply the active pharmaceutical ingredient strontium-82 to radiopharmaceutical companies for heart-imaging purposes. Until now, drug producers requiring strontium-82 have been mostly limited to Los Alamos National Laboratory and Brookhaven National Laboratory. Manhattan Isotope Technology will decrease the manufacturing burden on the U.S. government by commercializing LANL's patented strontium-82 production technology, which produces the ingredient by recycling expired strontium-82/rubidium-82 generators. Manhattan Isotope Technology's $100,000 VAF award will enable the company to develop, test, and validate a radioanalytical lab for strontium-82 manufacturing, establish environmental compliance, and gain acceptance from pharmaceutical manufacturers. The core project team includes Jason Kitten, Suzanne Kitten, and Larry Pitt.
Vista Therapeutics Inc. has developed NanoBioSensor™ technology that will revolutionize the measurement of biomarkers, such as proteins produced in response to trauma or disease. While existing biomarker measurement systems rely on occasional "snapshots" and expensive and time-consuming analysis, Vista's system will enable screening and immediate test results for large numbers of people, as well as continuous bedside monitoring. Vista will use its $100,000 VAF award to apply a novel technology for attaching antibodies to a silicon oxide surface in the company's Santa Fe facilities. This will enable the company to launch its first products in early 2012. The core project team includes Charles Lieber, Ph.D.; Spencer Farr, Ph.D.; Noah Clay, Ph.D.; and Mark Walztoni. Vista anticipates hiring 17 additional full-time, high wage employees by the end of 2013.
Los Alamos National Security, LLC, manager of Los Alamos National Laboratory, invests $1 million per year in economic development through a program known as Northern New Mexico Connect. Northern New Mexico Connect promotes VAF and a variety of other business
development programs. In the past seven years, companies have created and retained 168 jobs and attracted $7 million in new funding and financing as a result of their work with Northern New Mexico Connect.
About Los Alamos National Laboratory
Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is operated by Los Alamos National Security, LLC, a team composed of Bechtel National, the University of California, The Babcock & Wilcox Company, and URS for the Department of Energy’s National Nuclear Security Administration.
Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health, and global security concerns.
For more information, please click here
Copyright © Los Alamos National LaboratoryIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
Nanoscale view of energy storage January 16th, 2017
Recreating conditions inside stars with compact lasers: Scientists offer a new path to creating the extreme conditions found in stars, using ultra-short laser pulses irradiating nanowires January 12th, 2017
NIST physicists 'squeeze' light to cool microscopic drum below quantum limit January 12th, 2017
Nanoscale 'conversations' create complex, multi-layered structures: New technique leverages controlled interactions across surfaces to create self-assembled materials with unprecedented complexity December 22nd, 2016
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Strength of hair inspires new materials for body armor January 18th, 2017
Self-assembling particles brighten future of LED lighting January 18th, 2017
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016
Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016
NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016